Marwan Akar Appointed as President & Managing Director of Merck Canada

/ /

New Leadership at Merck Canada

Core to Merck’s vision is to encourage the growth of our employees, confident that their contributions will lead to a better world. Marwan Akar, the newly appointed President and Managing Director of Merck Canada embodies this vision.

Joining Merck in 1997, his journey with the company has taken him to the United States, Europe & Middle East and most recently as the Managing Director of Russia and Eurasia.

“I'm excited to join the Merck Canada team and contribute to the Canadian healthcare ecosystem, to truly help make a difference for patients.”

Marwan Akar,

President and Managing Director

• Has worked &/or lived in the United States, Middle East, Africa & Russia.
• Holds B.S. & M.S. degrees in Chemical Engineering from the University of Maryland and an MBA from Imperial College, London

Supporting Talent & Development

As we move through a transformative time with a renewed focus on oncology, vaccines and anti-viral therapies, Marwan is passionate about developing talent and encouraging Canadian students with an interest to explore opportunities within the pharmaceutical sector. “I am calling on all those with the shared desire to save and improve lives to join us.”

Read more about Marwan Akar here.

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.